Log in

Q11 Development and Manufacture of Drug Substances Q & A (Regarding the selection and justification of starting materials)

This draft guidance, When finalized, will Represent the current thinking of the Food and Drug Administration (FDA or Agency) is this topic. It Does not suit les Any rights for Any Person and is not binding on FDA or the public. You can use an alternative approach if it satisfying the requirements of the applicable statutes and règlements.


Final Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products

This guidance Describes and Explains the final rule on current Good Manufacturing Practice (CGMP) requirements for combination products That FDA Issued on January 22, 2013 (final rule).2 (21 Code of Federal Regulations (CFR) from 4). Prior to issuance of the final rule, ALTHOUGH CGMP règlements Were in place to suit les requirements for drugs, devices, biological products, and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT / Ps), There Were No règlements to Clarify and explain the implementation of These CGMP requirements to combination products. The final rule Did not suit les Any new requirements; It was Intended to Clarify qui CGMP requirements apply When drugs, devices, and biological products are combined to create combination products, and to set forth a transparent and streamlined Regulatory framework for firms to use When Demonstrating compliance with CGMP requirements applicable.


Guideline on validation process for finished products - information and data to be Provided in Regulatory submissions

This guideline replaces the previous Note for guidance on process validation (CPMP / QWP / 848 / 96, EMEA / CVMP / 598 / 99). The guideline is brought` into line with ICH Q8, Q9 and Q10 materials and the possibility to use continuous process verification in addition to, or INSTEAD of, traditional process validation Described in the previous guideline has-been added and is Encouraged. This guideline Does not Introduce new requirements on medicinal products already authorized and on the market, aim Clarifies how companies can take advantage of the new possibilities Given When Applying enhanced process understanding coupled with risk management tools under an efficient quality system as described by ICH Q8, Q9 and Q10.


EDQM Management of Documents and Records

Management of documentation and records is one of the pillars of a quality management system (QMS).

Several chapters of the ISO / IEC 17025 4.2 Management system, Document Control 4.3, 4.13 and 5.4.7 Control of records Control of data are dedicated to thesis topics.

Ce document replaces Guideline PA / PH / OMCL (97) 5 and the share of Guideline PA / PH / OMCL (07) 105 DEF related to the archiving of records.


Q11 Implementation Working Group Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological / Biological Entities) Questions and Answers

Since the ICH guideline Q11 Was finalised, worldwide experience with implementation of the recommendations on the development and manufacture of drug substances HAS Given rise to requests for clarification Relating to the selection and justification of starting materials. This Question and Answer (Q & A) document est Intended to Provide additional clarification and to Promote convergence on the considerations for the selection and justification of starting materials and on the information Provided That shoulds be in permission marketing applications and / or Master Files. The focus of the Q & A document est one chemical entity drug substances.


a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P
BROWSER A3P is a tool comprising the majority of links to texts, guides, regulatory documents and websites for the pharmaceutical, biotechnology and biomedical.
  • GMP & Guides

  • Country Sites

  • Regulatory Sites

  • Pharma areas

  • other Sites

   version 1.00                                                                                                               Youtube   linkedin